Oncolytic HSV Vectors and Anti-Tumor Immunity
Joseph C. Glorioso, Justus B. Cohen, William F. Goins, Bonnie L. Hall, Joseph W. Jackson, Gary Kohanbash, Nduka Amankulor, Balveen Kaur, Michael A. Caligiuri, E. Antonio Chiocca, Eric C. Holland, Christophe Quéva
Abstract
tumor-specific vaccines to elicit adaptive immunity. Oncolytic herpes simplex viruses (oHSVs) are among the most widely studied OVs for the treatment of solid malignancies, and Amgen's oHSV Imlygic® for the treatment of melanoma is the only OV approved in major markets. Here we describe important biological features of HSV that make it an attractive OV, clinical experience with HSV-based vectors, and strategies to increase applicability to cancer treatment.
Topics & Concepts
Oncolytic virusImmune systemLytic cycleHerpes simplex virusCTL*ImmunityAntigenCytotoxic T cellCancer researchVirotherapyMelanomaImmunologyBiologyImmunotherapyVirologyMedicineVirusCD8In vitroBiochemistryVirus-based gene therapy researchCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in Insects